GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » PS Ratio

Sage Therapeutics (Sage Therapeutics) PS Ratio : 9.19 (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sage Therapeutics's share price is $13.94. Sage Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.52. Hence, Sage Therapeutics's PS Ratio for today is 9.19.

Good Sign:

Sage Therapeutics Inc stock PS Ratio (=8.64) is close to 2-year low of 8.64

The historical rank and industry rank for Sage Therapeutics's PS Ratio or its related term are showing as below:

SAGE' s PS Ratio Range Over the Past 10 Years
Min: 1.87   Med: 219.88   Max: 5756.36
Current: 8.89

During the past 12 years, Sage Therapeutics's highest PS Ratio was 5756.36. The lowest was 1.87. And the median was 219.88.

SAGE's PS Ratio is ranked better than
51.15% of 997 companies
in the Biotechnology industry
Industry Median: 9.03 vs SAGE: 8.89

Sage Therapeutics's Revenue per Sharefor the three months ended in Mar. 2024 was $0.13. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.52.

Warning Sign:

Sage Therapeutics Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Sage Therapeutics was 866.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -59.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -17.90% per year.

During the past 12 years, Sage Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -1.30% per year. The lowest was -61.90% per year. And the median was -59.00% per year.

Back to Basics: PS Ratio


Sage Therapeutics PS Ratio Historical Data

The historical data trend for Sage Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics PS Ratio Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 534.74 4.12 393.89 293.38 15.00

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 267.26 271.79 108.89 15.00 12.35

Competitive Comparison of Sage Therapeutics's PS Ratio

For the Biotechnology subindustry, Sage Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's PS Ratio falls into.



Sage Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Sage Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=13.94/1.517
=9.19

Sage Therapeutics's Share Price of today is $13.94.
Sage Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.52.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Sage Therapeutics  (NAS:SAGE) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Sage Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (Sage Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Executives
Elizabeth Barrett director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas director, officer: See Remarks ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault officer: Chief Medical Officer C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi officer: Chief Commercial Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates director 88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud officer: Chief Scientific Officer 215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan officer: Chief Business Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook officer: General Counsel 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi officer: See Remarks 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035

Sage Therapeutics (Sage Therapeutics) Headlines